BIOMARKER FOR DETECTING COLORECTAL CANCER

1 . A colorectal cancer biomarker for detecting colorectal cancer, wherein the biomarker consists of at least one protein of the following 22 proteins with numbers 1 to 22, or at least one peptide of the partial peptides of the proteins with numbers 1 to 22:

1. Annexin A11 (ANXA 11) (SEQ ID NO: 1);

2. Annexin A3 (ANXA 3) (SEQ ID NO: 2);

3. Annexin A4 (ANXA 4) (SEQ ID NO: 3);

4. Tanascin-N(TNN) (SEQ ID NO: 4);

5. Transferrin receptor protein 1 (TFRC) (SEQ ID NO: 5);

6. Glucose transporter 1(GLUT-1) (SLC2A11) (SEQ ID NO: 6);

7. Complement component C9 (C9) (SEQ ID NO: 7);

8. CD88 antigen (C5AR1) (SEQ ID NO: 8);

9. 78 kDa glucose-regulated protein (HSPA5) (SEQ ID NO: 9);

10. α-1-acid glycoprotein (ORM1) (SEQ ID NO: 10);

11. Matrix metalloproteinase-9 (MMP9) (SEQ ID NO: 11);

12. Angiopoietin-1 (ANGPT1) (SEQ ID NO: 12);

13. CD67 antigen (CEACAM8) (SEQ ID NO: 13);

14. Mucin-5B (MUC5B) (SEQ ID NO: 14);

15. Adapter protein GRB2 (GRB2) (SEQ ID NO: 15);

16. Annexin A5 (Annexin A5) (ANXA 5) (SEQ ID NO: 16);

17. Olfactomedin-4 (OLFM4) (SEQ ID NO: 17);

18. Neutral amino acid transporter B(0) (SLC1A5) (SEQ ID NO: 18);

19. Tripeptidyl-peptidase 1 (TPP1) (SEQ ID NO: 19);

20. Heat shock-related 70 kDa protein 2 (HSPA2) (SEQ ID NO: 20);

21. Proteasome subunit α type-5 (PSMA5) (SEQ ID NO: 21); or

22. Neutrophil gelatinase-associated lipocalin (LCN2) (SEQ ID NO: 22).

2 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 1 , which consists of a combination of two or more proteins of the 22 proteins with numbers 1 to 22 according to claim 1 , or two or more peptides of the partial peptides of the proteins with numbers 1 to 22.

3 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 1 , wherein the partial peptides of the proteins with numbers 1 to 22 according to claim 1 are peptides consisting of the amino acid sequences as set forth in SEQ ID NOS: 23 to 59.

4 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 1 , which consists of at least one protein of the following 12 proteins, or at least one peptide of the partial peptides of the 12 proteins:

1. Annexin A11 (SEQ ID NO: 1);

2. Annexin A3 (SEQ ID NO: 2);

3. Annexin A4 (SEQ ID NO: 3);

4. Tanascin-N(SEQ ID NO: 4);

5. Transferrin receptor protein 1 (SEQ ID NO: 5);

6. Glucose transporter 1 (SEQ ID NO: 6);

8. CD88 antigen (SEQ ID NO: 8);

11. Matrix metalloproteinase-9 (SEQ ID NO: 11);

16. Annexin A5 (SEQ ID NO: 16);

17. Olfactomedin-4 (SEQ ID NO: 17);

19. Tripeptidyl-peptidase 1 (SEQ ID NO: 19); or

22. Neutrophil gelatinase-associated lipocalin (SEQ ID NO: 22).

5 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 4 , which consists of a combination of two or more proteins of the 12 proteins according to claim 4 , or two or more peptides of the partial peptides of the 12 proteins.

6 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 4 , wherein the partial peptides of the 12 proteins according to claim 4 are peptides consisting of the amino acid sequences as set forth in SEQ ID NOS: 23 to 34, 37, 38, 43, 44, 53, 54, 56 and 59.

7 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 1 , which consists of Annexin A4 or Annexin A11, or a partial peptide thereof.

8 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 7 , which consists of a combination of Annexin A4 and Annexin A11, or partial peptides of Annexin A4 and partial peptides of Annexin A11.

9 . The colorectal cancer biomarker for detecting colorectal cancer according to claim 7 , wherein the partial peptides of Annexin A4 and Annexin A11 are peptides consisting of the amino acid sequences as set forth in SEQ ID NOS: 23, 24, 27 and 28.

10 . A colorectal cancer biomarker for detecting colorectal cancer, which consists of a combination of the colorectal cancer biomarker according to claim 1 and CEA.

11 . A method of detecting colorectal cancer, comprising measuring the colorectal cancer biomarker according to claim 1 in a biological sample.

12 . A method of detecting colorectal cancer, comprising measuring the colorectal cancer biomarker according to claim 1 in a biological sample, and then determining that the subject is affected with colorectal cancer when the biomarker is present in a higher concentration in the biological sample than in a healthy subject.

13 . The method of detecting colorectal cancer according to claim 11 , wherein the biological sample is an extracellular vesicle (EV) in blood.

14 . The method of detecting colorectal cancer according to claim 11 , wherein the detection is carried out by an immunoassay or a mass spectrometry.

15 . A kit of detecting colorectal cancer, comprising an antibody reacting against the colorectal cancer biomarker according to claim 1 in the biological sample.